Literature DB >> 28043151

Identification of MAGEA12 as a prognostic outlier gene in gastric cancers.

J Wu, J Wang, W Shen.   

Abstract

Melanoma antigen (MAGE) family genes are frequently over-expressed in a subset population of multiple cancers, and serve as idea therapeutic targets; however, their distribution pattern in gastric cancers has not yet been evaluated. In this study, we first performed a cancer outlier profile analysis (COPA) on a series of public gene expression datasets of gastric cancer, and identified MAGEA12 showing a significant outlier expression model reproducibly. We further in silico validated that MAGEA12 outlier over-expression were associated with poor clinical outcome using six microarray datasets from GEO database. We then experimentally detected the MAGEA12 expression in an independent cohort of gastric cancer samples by immunohistochemistry, and showed that over-expression of MAGEA12 in a subset of cancers was associated with later stage and reduced survival; furthermore, MAGEA12 was an independent prognostic factor in an outlier manner. Our results indicate that MAGEA12 is a novel prognostic outlier gene in gastric cancers and patterns of MAGE expression may inform individualized targeted immunotherapies.

Entities:  

Keywords:  MAGE; MAGEA12; gastric cancer; prognosis outlier.

Mesh:

Substances:

Year:  2017        PMID: 28043151     DOI: 10.4149/neo_2017_210

Source DB:  PubMed          Journal:  Neoplasma        ISSN: 0028-2685            Impact factor:   2.575


  9 in total

1.  Scanning all chromosomal abnormalities with microarray-based comparative genomic hybridization in differential diagnosis of pediatric cancers.

Authors:  Hulya Tosun Yildirim; Safiye Aktas; Gulden Diniz; Tekincan Cagri Aktas; Burcin Baran; Serdar Bayrak; Zekiye Altun; Yasemin Cakir; Nur Olgun
Journal:  Int J Clin Exp Pathol       Date:  2019-08-01

2.  MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.

Authors:  Stefan Hartmann; Leonie Zwick; Mario J J Scheurer; Andreas R Fuchs; Roman C Brands; Axel Seher; Hartmut Böhm; Alexander C Kübler; Urs D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2017-10-15       Impact factor: 3.573

Review 3.  A Comprehensive Guide to the MAGE Family of Ubiquitin Ligases.

Authors:  Anna K Lee; Patrick Ryan Potts
Journal:  J Mol Biol       Date:  2017-03-11       Impact factor: 5.469

4.  High expression of MAGE-C1 gene in colorectal cancer is associated with its poor prognosis.

Authors:  Yu Tian; Ping Liang; Lihua Zhang; Xiufen Zhang; Xiaoli Wang; Yufen Jin; Xiaowei Qi; Yankui Liu
Journal:  J Gastrointest Oncol       Date:  2021-12

5.  DECO: decompose heterogeneous population cohorts for patient stratification and discovery of sample biomarkers using omic data profiling.

Authors:  F J Campos-Laborie; A Risueño; M Ortiz-Estévez; B Rosón-Burgo; C Droste; C Fontanillo; R Loos; J M Sánchez-Santos; M W Trotter; J De Las Rivas
Journal:  Bioinformatics       Date:  2019-10-01       Impact factor: 6.937

6.  Identification of novel prognostic biomarkers in renal cell carcinoma.

Authors:  Yuanzhang Zou; Qiu Lu; Qin Yao; Di Dong; Binghai Chen
Journal:  Aging (Albany NY)       Date:  2020-11-21       Impact factor: 5.682

7.  A five-gene based risk score with high prognostic value in colorectal cancer.

Authors:  Yida Pan; Hongyang Zhang; Mingming Zhang; Jie Zhu; Jianghong Yu; Bangting Wang; Jigang Qiu; Jun Zhang
Journal:  Oncol Lett       Date:  2017-09-28       Impact factor: 2.967

8.  Prognostic Value of Melanoma-Associated Antigen-A (MAGE-A) Gene Expression in Various Human Cancers: A Systematic Review and Meta-analysis of 7428 Patients and 44 Studies.

Authors:  Manish Poojary; Padacherri Vethil Jishnu; Shama Prasada Kabekkodu
Journal:  Mol Diagn Ther       Date:  2020-10       Impact factor: 4.074

9.  Resveratrol acts via melanoma-associated antigen A12 (MAGEA12)/protein kinase B (Akt) signaling to inhibit the proliferation of oral squamous cell carcinoma cells.

Authors:  Yu Shang; Yu-Ling Jiang; Li-Jun Ye; Li-Na Chen; Yue Ke
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.